Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) EBT Margin (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed EBT Margin for 16 consecutive years, with 5.51% as the latest value for Q3 2025.

  • On a quarterly basis, EBT Margin rose 1494.0% to 5.51% in Q3 2025 year-over-year; TTM through Sep 2025 was 76.74%, a 6307.0% decrease, with the full-year FY2024 number at 12.39%, down 1011.0% from a year prior.
  • EBT Margin was 5.51% for Q3 2025 at Harvard Bioscience, up from 11.02% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 11.71% in Q2 2022 to a low of 233.28% in Q1 2025.
  • A 5-year average of 20.73% and a median of 3.92% in 2023 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: soared 2724bps in 2023, then tumbled -21499bps in 2025.
  • Harvard Bioscience's EBT Margin stood at 3.42% in 2021, then plummeted by -192bps to 3.14% in 2022, then decreased by -25bps to 3.92% in 2023, then plummeted by -1237bps to 52.39% in 2024, then soared by 89bps to 5.51% in 2025.
  • Per Business Quant, the three most recent readings for HBIO's EBT Margin are 5.51% (Q3 2025), 11.02% (Q2 2025), and 233.28% (Q1 2025).